Clene To Present At Upcoming Investor Conferences
5 th Annual ROTH Healthcare Opportunities Conference
Date: September 29, 2026
Location: New York, NY
Format: 1x1 meetings
1x1 Meetings: Please contact your ROTH representative
Lytham Partners Investor Conference Fall Event
Date: September 29-30, 2026
Time of Presentation: 9:45 am ET
Location: Virtual
Format: Presentation and 1x1 meetings
1x1 Meetings: Please contact your Lytham representative
Webcast: link to webcast
A webcast of the presentation will be available on the“Events” section of the Clene website or using the webcast links above.
About Clene
Clene Inc., (Nasdaq: CLNN) (along with its subsidiaries,“Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit or follow us on X (formerly Twitter) and LinkedIn.
Investor Contact: Kevin Gardner, LifeSci Advisors; ...; 617-283-2856
Media Contact: Caroline Wagner, FTP; ...; (267) 294-6563
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment